StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
BIAF reports on 2026-05-20 during the day. Things to look at before the print:
Educational pre-print checklist — descriptive only, not a directional call.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.93 | $1.97 | +2.07% | 0.2M |
| 05-12 | $2.10 | $1.88 | -10.48% | 0.7M |
| 05-13 | $1.88 | $1.89 | +0.53% | 0.2M |
| 05-14 | $1.88 | $1.99 | +5.85% | 0.2M |
| 05-15 | $1.92 | $1.88 | -2.08% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Each factor shows BIAF's percentile within the scored universe — observational ranking, not a recommendation.
| Metric | Q2 2026 (Est.) Expected 2026-05-20 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $1.51M | $1.35M | $6.16M | $4.57M | $3.12M |
Operating Income | Not available | $-3.62M | $-10.57M | $-7.44M | $-5.14M |
Net Income | Not available | $-3.63M | $-14.91M | $-11.77M | $-6.72M |
EPS (Diluted) | $-2.45 | $-0.81 | $-8.66 | $-7.55 | $-0.20 |
Total Assets | Not available | $7.95M | $10.96M | $11.55M | $4.75M |
Total Liabilities | Not available | $4.28M | $3.68M | $2.64M | $6.89M |
Cash & Equivalents | Not available | $3.10M | $6.45M | $7.67M | $802.84K |
Free Cash Flow OCF − CapEx | Not available | $-3.23M | $-9.39M | $-6.83M | $-4.35M |
Shares Outstanding | Not available | 4.50M | 4.50M | 3.47M | 28.46M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.